These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 35973976)

  • 1. Targeted Therapies in Pheochromocytoma and Paraganglioma.
    Wang K; Crona J; Beuschlein F; Grossman AB; Pacak K; Nölting S
    J Clin Endocrinol Metab; 2022 Nov; 107(11):2963-2972. PubMed ID: 35973976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures.
    Wang K; Schütze I; Gulde S; Bechmann N; Richter S; Helm J; Lauseker M; Maurer J; Reul A; Spoettl G; Klink B; William D; Knösel T; Friemel J; Bihl M; Weber A; Fankhauser M; Schober L; Vetter D; Broglie Däppen M; Ziegler CG; Ullrich M; Pietzsch J; Bornstein SR; Lottspeich C; Kroiss M; Fassnacht M; Wenter VUJ; Ladurner R; Hantel C; Reincke M; Eisenhofer G; Grossman AB; Pacak K; Beuschlein F; Auernhammer CJ; Pellegata NS; Nölting S
    Endocr Relat Cancer; 2022 May; 29(6):285-306. PubMed ID: 35324454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
    Toledo RA
    Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview.
    De Filpo G; Maggi M; Mannelli M; Canu L
    J Endocrinol Invest; 2021 Jan; 44(1):15-25. PubMed ID: 32602077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic therapies for pheochromocytoma and paraganglioma.
    Jimenez C; Fazeli S; Román-Gonzalez A
    Endocr Relat Cancer; 2020 Jul; 27(7):R239-R254. PubMed ID: 32369773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.
    Peng S; Zhang J; Tan X; Huang Y; Xu J; Silk N; Zhang D; Liu Q; Jiang J
    Front Endocrinol (Lausanne); 2020; 11():586857. PubMed ID: 33329393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma.
    Wang Y; Liu B; Li F; Zhang Y; Gao X; Wang Y; Zhou H
    Front Endocrinol (Lausanne); 2023; 14():1274239. PubMed ID: 37867526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic pheochromocytomas and paragangliomas: where are we?
    Prinzi N; Corti F; Torchio M; Niger M; Antista M; Pagani F; Beninato T; Pulice I; Rossi RE; Coppa J; Cascella T; Giacomelli L; Di Bartolomeo M; Milione M; de Braud F; Pusceddu S
    Tumori; 2022 Dec; 108(6):526-540. PubMed ID: 35593402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas.
    Bechmann N; Moskopp ML; Ullrich M; Calsina B; Wallace PW; Richter S; Friedemann M; Langton K; Fliedner SMJ; Timmers HJLM; Nölting S; Beuschlein F; Fassnacht M; Prejbisz A; Pacak K; Ghayee HK; Bornstein SR; Dieterich P; Pietzsch J; Wielockx B; Robledo M; Qin N; Eisenhofer G
    Endocr Relat Cancer; 2020 Nov; 27(11):625-640. PubMed ID: 33112842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic Pheochromocytomas and Abdominal Paragangliomas.
    Granberg D; Juhlin CC; Falhammar H
    J Clin Endocrinol Metab; 2021 Apr; 106(5):e1937-e1952. PubMed ID: 33462603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opposing Effects of Cannabidiol in Patient-derived Neuroendocrine Tumor, Pheochromocytoma/Paraganglioma Primary Cultures.
    Wang K; Schober L; Fischer A; Bechmann N; Maurer J; Peischer L; Reul A; Hantel C; Reincke M; Beuschlein F; Robledo M; Mohr H; Pellegata NS; Schilbach K; Knösel T; Ilmer M; Angele M; Kroiss M; Maccio U; Broglie-Däppen M; Vetter D; Lehmann K; Pacak K; Grossman AB; Auernhammer CJ; Zitzmann K; Nölting S
    J Clin Endocrinol Metab; 2024 Oct; 109(11):2892-2904. PubMed ID: 38605427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients with Metastatic Pheochromocytomas/Paragangliomas.
    Zhou Y; Cui Y; Zhang D; Tong A
    J Clin Endocrinol Metab; 2023 Feb; 108(3):755-766. PubMed ID: 36383456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas.
    Mete O; Pakbaz S; Lerario AM; Giordano TJ; Asa SL
    Am J Surg Pathol; 2021 Sep; 45(9):1264-1273. PubMed ID: 33826547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant pheochromocytoma and paraganglioma: management options.
    Corssmit EPM; Snel M; Kapiteijn E
    Curr Opin Oncol; 2020 Jan; 32(1):20-26. PubMed ID: 31599769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial.
    Nasca V; Prinzi N; Coppa J; Prisciandaro M; Oldani S; Ghelardi F; Conca E; Capone I; Busico A; Perrone F; Tamborini E; Sabella G; Greco G; Greco FG; Tafuto S; Procopio G; Morano F; Niger M; Maccauro M; Milione M; de Braud F; Pietrantonio F; Pusceddu S
    Eur J Cancer; 2024 Sep; 209():114276. PubMed ID: 39128186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
    Perez K; Jacene H; Hornick JL; Ma C; Vaz N; Brais LK; Alexander H; Baddoo W; Astone K; Esplin ED; Garcia J; Halperin DM; Kulke MH; Chan JA
    Endocr Relat Cancer; 2022 Sep; 29(9):533-544. PubMed ID: 35731023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of targeted therapies in Sdhb-mutated tumors.
    Moog S; Salgues B; Braik-Djellas Y; Viel T; Balvay D; Autret G; Robidel E; Gimenez-Roqueplo AP; Tavitian B; Lussey-Lepoutre C; Favier J
    Endocr Relat Cancer; 2022 May; 29(6):375-388. PubMed ID: 35348472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors.
    Toledo R; Jimenez C
    F1000Res; 2018; 7():. PubMed ID: 30109021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.
    Taïeb D; Jha A; Treglia G; Pacak K
    Endocr Relat Cancer; 2019 Nov; 26(11):R627-R652. PubMed ID: 31561209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
    Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
    Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.